Pancreatic Glucose Uptake in Vivo in Men with Newly

ORIGINAL E n d o c r i n e

ARTICLE R e s e a r c h

Pancreatic Glucose Uptake in Vivo in Men with Newly Diagnosed Type 1 Diabetes Teemu Kalliokoski, Pirjo Nuutila, Kirsi A. Virtanen, Patricia Iozzo, Marco Bucci, Erkki Svedstro¨m, Anne Roivainen, Kjell Någren, Tapio Viljanen, Heikki Minn, Juhani Knuuti, Tapani Ro¨nnemaa, and Olli Simell Departments of Pediatrics (T.K., O.S.), Medicine (P.N., T.R.), and Radiology (E.S.) and Turku PET Centre (P.N., K.A.V., P.I., M.B., A.R., K.N., T.V., H.M., J.K.), University of Turku, 20521 Turku, Finland; and Department of Pediatrics (T.K.), Central Hospital of Seina¨joki, 60220 Seina¨joki, Finland

Context: Due to the restricted accessibility of pancreatic tissue in living man, direct analysis of the events preceding development of autoimmune changes in the pancreas has been problematic. In vivo imaging of insulitis might markedly increase understanding of the events and timing of the events that are necessary for the progression toward overt type 1 diabetes. Design: To evaluate possibilities to visualize insulitis in man in vivo with positron emission tomography, we studied 12 male patients (age 26 ⫾ 7 yr) with newly diagnosed type 1 diabetes (duration range 0 –7 months) and nine age- and sex-matched healthy controls after an overnight fast using 2-[18F]fluoro-2-deoxy-D-glucose and [11C]methionine. For definition of the regions of interest, pancreas was localized with magnetic resonance imaging or computed tomography-positron emission tomography. Results: Glucose uptake to the pancreas was markedly higher in the patients with type 1 diabetes than in the healthy controls (22.9 ⫾ 6.4 vs. 17.8 ⫾ 6.0 ␮mol/kg䡠min, P ⫽ 0.039). Glucose uptake to the pancreas of the patients was inversely associated with the duration of diabetes (r ⫽ ⫺0.58; P ⫽ 0.024), so that in patients with newly diagnosed type 1 diabetes, glucose uptake was higher than in the healthy controls or patients with long duration of diabetes. Methionine uptake to the pancreas of the patients was similar as in the controls (3.7 ⫾ 1.9 vs. 4.6 ⫾ 2.4 ␮mol/kg䡠min, P ⫽ 0.21). Conclusions: In patients with type 1 diabetes, glucose uptake to the pancreas is enhanced at or soon after the time of diagnosis. (J Clin Endocrinol Metab 93: 1909 –1914, 2008)

he pathological hallmark of the autoimmune type 1 (insulindependent) diabetes mellitus is infiltration of the pancreatic islets and their surroundings predominantly with lymphocytes (insulitis). Insulitis develops usually long before the onset of the clinical disease and is also present in the nonobese diabetes (NOD) mouse, always at the time of hyperglycemia (1). It is highly likely that insulitis development in man follows a similar pattern (2). Due to the restricted accessibility of pancreatic tissue in living man, direct analysis of the events preceding and after development of autoimmune changes in the pancreas has been problematic. In vivo imaging of insulitis might thus markedly increase understanding of the events and timing of the events that

T

are necessary for the progression toward overt diabetes and also help in defining potential molecular targets for prevention of autoimmunity and type 1 diabetes. Imaging of inflammation by nuclear medicine has earlier been based on nonspecific visualization due to increased vascular permeability in the acute phase (3–5). The first methods for in vivo imaging of inflammation in the pancreatic islets were developed by Signore and co-workers (6, 7), who visualized insulitis in vivo in the NOD mouse using scintigraphy and 123I-labeled IL-2. In some clinical applications, acute inflammatory lesions have been accurately localized using labeled white blood cells and scintigraphy. However, when the inflammatory lesion ages, neutrophil

0021-972X/08/$15.00/0

Abbreviations: CT, Computed tomography; FDG, fluoro-2-deoxy-D-glucose; HbA1c, glycosylated hemoglobin; ICA, islet cell autoantibodies; JDFU, Juvenile Diabetes Foundation units; MRI, magnetic resonance imaging; NOD, nonobese diabetic; PET, positron emission tomography; ROI, regions of interest.

Printed in U.S.A. Copyright © 2008 by The Endocrine Society doi: 10.1210/jc.2006-2533 Received November 17, 2006. Accepted February 11, 2008. First Published Online February 19, 2008

J Clin Endocrinol Metab, May 2008, 93(5):1909 –1914

Downloaded from jcem.endojournals.org at Univ Turku Library Med Fac on April 26, 2009

jcem.endojournals.org

1909

1910

Kalliokoski et al.

Pancreatic Glucose Uptake in Type 1 Diabetic Men


turnover at the site decreases as they are increasingly replaced by mononuclear cells, diminishing accuracy of the leukocyte scan. Recently, new approaches toward ␤-cell and inflammatory cell imaging have been introduced, but they have offered no solution to the in vivo imaging of insulitis (8 –10). Positron emission tomography (PET) makes quantitative and accurate measurement of regional metabolism possible. It also overcomes most of the physical limitations of other imaging or invasive techniques by enabling true quantification of physiological processes (11). 2-[18F]Fluoro-2-deoxy-D-glucose ([18F]FDG) has turned out to be a useful tumor-detecting agent due to the enhanced glucose utilization by the neoplastic and inflammatory cells in tumors (12). It is efficiently taken up by activated inflammatory cells and can be used to quantify their glucose uptake (13). Studies from the 1980s show that glucose uptake by proliferating thymocytes during an acute experimental inflammation can be as high as 56-fold compared with the uptake by resting thymocytes (14, 15). Increased glucose metabolism is reflected in the higher [18F]FDG uptake, suggesting that also subacute and chronic inflammations might be detectable with [18F]FDG PET. We have earlier shown with [18F]FDG in prediabetic NOD mice that uptake of radioactivity to the islets affected with insulitis is up to 2.3 times higher than uptake to islets in the same pancreas that remained unaffected by insulitis or to the islets in the healthy BALB/c mice (16). Methionine is an essential amino acid needed for protein synthesis, transmethylation reactions and polyamine synthesis and as a precursor for transsulfuration pathways. Amino acids like [11C]methionine (T ⁄ ⫽ 20.4 min) have been widely used as tracers for detection of malignancies with PET. The uptake of [18F]FDG to normal human pancreas is modest, but methionine is taken up by the pancreas much more intensely than by the surrounding tissues (17). In the rat, [11C]methionine accumulates in the pancreas, liver, kidney, and spleen, in decreasing order (18). [18F]FDG is a labeled glucose analog in which one

hydroxyl group is replaced by fluorine-18 (T ⁄ ⫽ 109.8 min). [18F]FDG is transported into the cell by the same carriers as glucose and phosphorylated to [18F]FDG-6-phosphate ([18F]FDG-6-P) by hexokinases. After phosphorylation, [18F]FDG-6-P can be incorporated into glycogen, but it cannot enter glycolysis and is irreversibly trapped in the cell. We have now investigated adult male patients with newly diagnosed type 1 diabetes and their healthy age- and sexmatched controls using [11C]methionine and [18F]FDG PET to evaluate whether these methods enable visualization of the inflammatory process in the islets and their surrounding tissue in the pancreas.

12

TABLE 1.

Age (yr) 19 20 21 21 22 22 22 24 32 33 35 40 41

12

Subjects and Methods Subjects A total of 16 adult male patients (age 27 ⫾ 8 yr, mean ⫾ SD) with newly diagnosed multiple autoantibody-positive type 1 diabetes participated in the study. The patients had classical symptoms of type 1 diabetes and fulfilled the World Health Organization diagnostic criteria. The control group included nine age-matched healthy men without any medication. None of the subjects had clinical symptoms of pancreatitis. The nature, purpose, and potential risks of the study were explained to all subjects as part of the written informed consent procedure. The Ethics Committee of the Turku University Hospital approved the study. PET data were not obtained in one patient due to technical problems during the study. One patient was in clinical remission requiring daily only 2 IU of short-acting insulin before breakfast. Therefore, he was excluded from the final analysis. Two additional patients were excluded from the study because normoglycemia was not achieved during the PET study. Twelve type 1 diabetic patients and nine control subjects were included in the final analysis (Table 1).

Study design All patients underwent [18F]FDG PET studies no later than 7 months after the diagnosis of type 1 diabetes. The [11C]methionine study was performed with nine diabetic patients and seven healthy controls. All subjects were studied after an overnight fast (12 h). Patients with diabetes

Characteristics of the patients with type 1 diabetes included in the study

Body mass index (kg/m2)

Duration of diabetes (months)

Insulin dosage (IU/kg䡠d)

Fasting C-peptide (nmol/liter)

20.1 21.6 17.7 20.0 17.5 19.6 20.0 23.5 25.6 23.2 28.1 21.9 25.1

2.0 6.8 0.3 2.0 0.7 0.8 0.4 6.0 5.0 0.3 3.0 0.4 0a

0.49 0.36 1.10 0.69 0.58 0.59 0.95 0.23 0.52 0.73 0.22 0.29 0.02

0.29 ⬍0.13 0.26 0.15 0.15 0.15 0.24 0.14 0.26 0.15 0.16 0.68

Autoantibodies (RU) HbA1c (%)

ICA (JDFU)

Glutamic acid decarboxylase

IA-2 protein

Insulin

9.9 13.5 12.2 15.3 10.2 15.3 13.1 12.0 15.2 10.3 14.1 10.5 7.3

110.0 49.0 15.0 96.0 0.0 15.0 13.0 15.0 8.0 28.0 219.0 8.0 7.0

157.7 47.0 5.9 5.2 8.6 149.8 29.8 39.3 4.7

0.1 100.4 68.0 80.2 0.1 0.1 0.3 105.6 23.2 1.3 44.3 7.0 11.9

137.3 264.5 1.0 3.0 127.2 1.0 5.0 1.0 103.9 5.1 46.9 28.5 1.8

155.5 117.8 14.8

Fasting C-peptide and HbA1c values were measured at the time of diagnosis of diabetes. Diabetes-associated autoantibodies and body mass index were measured at the time of the PET study. Positive autoantibody values are shown in bold. Daily insulin dose included both long- and short-acting insulin at the time of the PET study. RU, Relative units. a

The last patient is considered to be in remission and has been excluded from the analysis.




1911

then dividing this by the lumped constant, which is a correction factor for the tissue. A lumped constant value of 1.0 for pancreas and 1.2 for skeletal muscle was used, as described (24). The rate of methionine uptake was calculated by multiplying Ki by plasma methionine concentration. FIG. 1. An example of MRI, [11C]methionine, and [18F]FDG PET images from the abdominal region of a patient with type 1 diabetes. Pancreas is circled in the MRI and [18F]FDG PET images. In PET images, the highest activity is shown as red as an index of trapping. The color scales in methionine and [18F]FDG PET images are different to maximize the contrast between tissues. Therefore, the activities shown by the two color scales are incomparable with each other. The red spot in the [18F]FDG image shows high activity in the kidney as [18F]FDG is excreted to the urine.

were rendered normoglycemic before the start of the study. The regular dose of intermediate or long-acting insulin was reduced by half, and short-acting insulin was withdrawn on the morning of the study. For anatomical localization of the pancreas, either magnetic resonance imaging (MRI) scan (n ⫽ 18) or computed tomography (CT) (n ⫽ 7) was used.

PET study protocol GE Advance Scanner (General Electric Medical Systems, Milwaukee, WI) and Discovery VCT scanner (General Electric Medical Systems) were used for imaging. Final in-plane resolutions of the reconstructed PET images were 7.4 and 4.8 mm (19), respectively. Photon attenuation was measured with a 5-min transmission scan, using a removable ring source containing 68Ge, or with CT. Either CT or MRI was used for anatomical reference. In the beginning of the PET study, a catheter was inserted in the antecubital vein for infusion of glucose, insulin, and bolus injections of [11C]methionine and [18F]FDG. Another catheter was inserted in a vein of the contralateral hand, which was warmed for sampling of arterialized venous blood. The study subject was placed in a supine position in the gantry of the PET camera. At 0 min, 280 –360 MBq of [11C]methionine was injected into the antecubital vein over 2 min, and a dynamic scan (40 min; four 30-sec, three 60-sec, five 180-sec, and four 300-sec frames) of the abdominal region was obtained. Plasma radioactivity samples were collected during each time frame. [18F]FDG scanning was started more than 2 h (six times 11C half-life) after the methionine injection to allow decay of the [11C] radioactivity. Then, 250 MBq [18F]FDG was injected iv over 2 min, and a dynamic PET scan (60 min; four 30-sec, three 60-sec, five 180-sec, four 300-sec, and two 600-sec frames) was initiated at the time of the injection. Plasma radioactivity samples were collected during each time frame. During PET studies, normoglycemia was maintained using a variable-rate infusion of 20% glucose. If blood glucose concentration exceeded 7 mmol/liter during the study, a euglycemic insulin clamp was started with low insulin dose (0.2 mU/kg䡠min) (20).

Production of PET tracers

[11C]Methionine was prepared as described (25). The radiochemical purity exceeded 92%, and the specific radioactivity was 37 MBq/nmol (26). [18F]FDG was synthesized with a computercontrolled apparatus, according to a modified method of Hamacher et al. (27). The radiochemical purity exceeded 98%, and the specific radioactivity was 76 MBq/nmol.

MRI MRI was done with GE Signa Horizon LX Echo Speed 1.5T (General Electric Medical Systems) with a body coil. Transverse T1-weighted field echo images with time of repetition of 124 msec and time of echo of 5 msec were obtained with the same pixel size as the PET images. Subjects fasted for at least 6 h before the MRI to minimize bowel movements.

Biochemical and radiochemical analysis Before the PET study, blood samples were drawn after a 10- to 12-h overnight fast for measurement of islet cell autoantibodies (ICA), glucose, and insulin in serum or plasma. ICA were measured using a standard indirect immunofluorescence assay on a section of frozen human pancreas from a blood group O donor (28, 29). ICA-positive sera were diluted sequentially to find endpoint titers, and the results were expressed in Juvenile Diabetes Foundation units (JDFU). The assay was 100% sensitive and 98% specific in the International Workshop of the Standardization of the ICA (30). The detection limit of the assay is 2.5 JDFU. Autoantibodies to insulin, glutamic acid decarboxylase, and IA-2 protein were measured as described (31). Plasma samples for immunoreactive free insulin were immediately precipitated with polyethylene glycol (32). Fasting insulin and plasma Cpeptide were assessed by RIA using commercial kits (Pharmacia In-

Data analysis Tissue time-activity curves were derived from regions of interest (ROI) placed in the body and head of the pancreas as well as in the erector spinae muscle, according to the anatomical reference of MRI or CT (Figs. 1 and 2). In studies using MRI to locate the pancreas in PET images, ROI were placed in the transaxial MRI picture with the same zoom as the PET images (Fig. 1). ROI were copied from MRI sections to corresponding planes in the [11C]methionine image to confirm their correct positioning, and then ROI were copied to the [18F]FDG planes using the same zoom and thickness. Radioactivity of [11C]methionine and [18F]FDG, measured in arterialized venous blood samples over time, was used as input function. The three-compartment model of [11C]methionine and [18F]FDG kinetics (21) and graphical analysis (22) were used to quantify the fractional uptake rates. The plasma curve was used for graphic analysis of [18F]FDG and [11C]methionine influx as described (23). The slopes of the plot (Ki) in graphical analysis are equal to the utilization rate constants of [11C]methionine and [18F]FDG. The rate of glucose uptake is calculated by multiplying Ki by the plasma glucose concentration and

FIG. 2. With new CT-PET technology, both anatomy and PET imaging can be achieved in a single scan. CT and PET planes are fused, and ROI can be drawn to this image. In PET images, the highest activity is shown as red as an index of trapping; green shows moderate and blue low [18F]FDG uptake.


1912

A

45.0 40.0

Kalliokoski et al.



method. All data are presented as mean ⫾ SD. Pearson correlation test was used for analysis of correlation. Significance was set at ⬍0.05.

Glucose Uptake (10 -3 )

35.0 30.0 25.0

Results

20.0

Twelve newly diagnosed male patients with type 1 diabetes who were positive for multiple diabetes-associated autoantibodies and 10.0 nine healthy age- and sex-matched controls 5.0 were included in the final analysis (Table 1). 0.0 Plasma glucose concentration was within Control 2.0 6.0 0.0 1.0 3.0 4.0 5.0 7.0 Subjects the normoglycemic range during the study Duration of Diabetes (months) sessions in both groups but slightly higher in the patients than in the healthy control subB 35.0 jects during the PET studies (5.9 ⫾ 0.5 vs. 5.3 ⫾ 0.5 mmol/liter, P ⬍ 0.01). Plasma me30.0 thionine concentration was similar in the pa25.0 tients and in the healthy subjects (18.8 ⫾ 5.4 vs. 22.1 ⫾ 5.0 ␮mol/liter, P ⫽ 0.12). Insulin 20.0 concentration was higher in the patients with diabetes than in the controls (11.1 ⫾ 15.0 6.1 vs. 5.5 ⫾ 4.1 mU/liter, P ⫽ 0.02). 10.0 Glucose uptake to the pancreas was higher in the patients with newly diagnosed 5.0 diabetes than in the healthy subjects (22.9 ⫾ 0.0 6.4 vs. 17.8 ⫾ 6.0 ␮mol/kg䡠min, P ⫽ 0.039). 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 Control Glucose uptake associated inversely with the subjects Duration of Diabe te s (months) duration of diabetes (r ⫽ ⫺0.58; P ⫽ 0.024) FIG. 3. Glucose uptake to the pancreas (A) and muscle (B) in 12 patients with type 1 diabetes up (Fig. 3A) and was markedly higher in the to 7 months after the diagnosis (䉬). The studies were performed using a PET scan and [18F]FDG. patients who were studied shortly after the One of the patients was considered to be in remission (⫻) (for details, see Subjects and Methods). Glucose uptake of control subjects has been shown in the same scale as a group (E). Glucose diagnosis of type 1 diabetes than in the pauptake (millimoles per kilogram per minute) to the pancreas shows good correlation with the tients examined a few months later. It is of duration of diabetes (r ⫽ ⫺0.58; P value ⫽ 0.024). Glucose uptake to the muscle differs clearly interest that the highest glucose uptake to from the uptake to the pancreas. the pancreas (38.9 ␮mol/kg䡠min) was found in the patient who had type 1 diabetes diagsulin RA kit from Pharmacia Diagnostica, Uppsala, Sweden, and nosed at a very early stage in normal routine checkup at the age Euria-C-peptide from Eurodiagnostica, Malmo¨, Sweden). Glycosyof 40 yr. He had abnormal oral glucose tolerance test, and therelated hemoglobin (HbA1c) was measured with HPLC (Variant Anafore, insulin medication was started. He was positive for three of lyzer; Bio-Rad, Hercules, CA) with reference values of 4.0 – 6.0%. four type 1 diabetes-specific autoantibodies studied (Table 1). Both fasting C-peptide and HbA1c were measured at the diagnosis of type 1 diabetes. Glucose concentration in arterialized venous blood His PET study was done 7 months after the initiation of daily sc was determined every 10 min using glucose oxidase method (Analox insulin. At the time of scanning, he needed only a daily dose of GM7 Analyser; Analox Instruments, Hammersmith, UK). Heart rate 2 IU of short-acting insulin at breakfast and was considered to be and blood pressure were monitored every 15 min during the PET in remission. Therefore, his pancreatic glucose uptake has not studies. Plasma radioactivity was measured with an automatic ␥-counter been included in the calculation of the mean values. (Wizard 1480 3“; PerkinElmer-Wallac, Turku, Finland) from blood Skeletal muscle glucose uptake was closely similar in the pasamples drawn at every time frame. All data were corrected for dead tients with diabetes and the healthy controls (11.5 ⫾ 7.7 vs. 9.2 ⫾ 11 time, decay, and measured photon attenuation. Radioactive [ C]me3.2 ␮mol/kg䡠min, P ⫽ 0.20). It shows a significant association thionine metabolites of plasma were analyzed at 0, 20, and 40 min after the injection. The low molecular weight fraction of [11C]methiwith the duration of diabetes (r ⫽ 0.55; P ⫽ 0.03), but the value onine metabolites in plasma were separated by fast-gel filtration using is driven very strongly by one subject (Fig. 3B). Pancreatic gluSephadex PD-10 column (Pharmacia Fine Chemicals, Uppsala, cose uptake was not associated with plasma insulin concentraSweden). tions, daily sc insulin dose, or autoantibody titers. Pancreatic glucose uptake values and fasting C-peptide concentrations Statistical analysis showed rather good correlation (r ⫽ 0.62; P ⬍ 0.05). However, Statistical analysis was performed using SAS System for Windows pancreatic glucose uptake and HbA1c values were not associated release 8.2 (SAS, Cary, NC). Shapiro-Wilks test was performed to test normal distribution, and one-way ANOVA was used as a parametric (r ⫽ ⫺0.35; P ⫽ 0.26). Glucose Uptake (10

-3

)

15.0



In contrast to glucose, methionine uptake to the pancreas and skeletal muscle was similar in the patients and in the controls (3.7 ⫾ 1.9 vs. 4.6 ⫾ 2.4 ␮mol/kg䡠min and 0.38 ⫾ 0.32 vs. 0.32 ⫾ 0.09 ␮mol/kg䡠min, respectively; P for both was nonsignificant). Methionine uptake was not associated with pancreatic glucose uptake or duration of diabetes.

Discussion The data from our PET study indicate that glucose uptake to the pancreas of patients with newly diagnosed type 1 diabetes is increased. The pancreatic uptake values were highest at the time of diagnosis of clinical diabetes and decreased to the levels of healthy subjects within 3– 6 months. Pancreatic methionine uptake shows a different temporal pattern, because it is similar in the diabetic patients at the time of diagnosis to that in the healthy control subjects. We have previously shown that the mean [18F]FDG uptake by the islets of Langerhans is elevated in prediabetic and diabetic NOD mice with insulitis. The extent of insulitis varied markedly in the NOD mice of all ages, so that in pancreas sections, only some of the islets were infiltrated. All NOD mice with insulitis had also regions in the pancreas with entirely intact islets, often in groups of several islets in the same intact tissue section. NOD islets with no inflammation showed similar [18F]FDG uptake ratios as the healthy BALB/c islets and the surrounding exocrine pancreas (16). Our current findings suggest that glucose uptake to the human pancreas is increased at the time of diagnosis of type 1 diabetes (Fig. 3A). After the diagnosis and onset of insulin therapy, the number of the insulin-producing ␤-cells as well as the activity of the islet-infiltrating lymphocytes probably gradually decreases, leading to a return of the uptake of glucose in the pancreas to the baseline values within 3– 6 months of the diagnosis of type 1 diabetes. Previous studies suggest that amino acids are taken up by inflammatory cells less actively than [18F]FDG, probably because protein metabolism in inflammatory cells is less active than glucose metabolism (33). This may to some extent explain why in this study methionine uptake to the pancreas was slightly lower in the patients with type 1 diabetes than in the controls. It is also possible that the patients with diabetes may have been in a mild catabolic state due to fasting, which could also explain the decrease in the methionine uptake to the pancreas. Altogether, our results obtained with the glucose and methionine tracers are in accord with the findings of a local inflammation, characterized typically by higher uptake of glucose than of methionine or other amino acids. Although insulitis and other inflammatory processes like pancreatitis cannot be absolutely differentiated from each other based on the [18F]FDG and [11C]methionine uptake only (34), the fact that our patients had no history or clinical evidence of pancreatitis suggests that the patients had insulitis, possibly in combination with other type 1 diabetes-associated metabolic and circulatory findings. Interestingly, the time period during which glucose uptake showed the


1913

strongest increase overlapped quite well with the time of the expected peak activity of insulitis. It is of note that in this study, glucose uptake correlated rather well with the markers of severity of the metabolic derangement at the time of diagnosis of type 1 diabetes. Pancreatic glucose uptake showed positive association with serum fasted C-peptide values, suggesting that additional unknown factors may have modified the events that precede development of overt type 1 diabetes. We thus propose that the overall rate and extent of accumulation of inflammatory cells and velocity of ␤-cell destruction may markedly differ among individuals. The severity of the metabolic derangement at diagnosis may reflect the immensity of the preceding inflammatory destruction. Furthermore, there may be some delay in the manifestation of the metabolic imbalance with respect to the causal inflammatory reaction. Finally, several potential confounding factors beyond destructive autoimmunity may regulate glucose control at this stage, so that glucose itself may be a poor marker of the overall functional status of the remaining ␤-cells. In animal experiments, [18F]FDG uptake to inflammatory lesions is markedly reduced during hyperglycemia, whereas uptake to tumors remains unaltered (35). In our study, the diabetic subjects had slightly higher mean plasma glucose concentration than the healthy controls. Thus, the difference in glucose uptake between the diabetic and control subjects might have been slightly more pronounced if both groups had had strictly identical glucose concentration during the PET study. However, multiple regression analysis showed that in this study, plasma insulin had no influence on glucose uptake to the pancreas. In simple regression analysis, the time since diagnosis of type 1 diabetes correlated nicely with glucose uptake to the pancreas. In conclusion, glucose uptake to the pancreas of patients with newly diagnosed type 1 diabetes is higher than that of healthy age- and sex-matched control subjects. Despite the fact that the number of subjects studied was small, the data suggest that [18F]FDG-based PET technology can possibly be used for rough estimation of the extent of insulitis in man. To confirm the validity of this imaging approach, repeated studies of subjects with increased risk of developing type 1 diabetes are needed to evaluate the method used. Use of the recently introduced CT-PET, which further improves anatomical localization of the pancreas in the images, in combination with new, more specific signaling molecules, may lead to discovery of new imaging technologies that may markedly improve early identification of subjects with increased risk of progression to overt type 1 diabetes.

Acknowledgments We are grateful to Heikki Oivanen, Markku Komu, Mika Tera¨s, Marko Seppa¨nen, and Anna Karmi for excellent technical assistance. We thank Pirkko Korsoff, Kari Va¨isa¨nen, and the staff members at the Departments of Medicine at the University Hospital of Turku and Central Hospital of Seina¨joki for their excellent collaboration. Address all correspondence and requests for reprints to: Teemu Kalliokoski, Department of Pediatrics, Central Hospital of Seina¨joki, Hanneksenrinne 7, 60220 Seina¨joki, Finland. E-mail: [email protected]. This work was funded partly by Juvenile Diabetes Research Foun-


1914

Kalliokoski et al.



dation International (Grants 4-1999-731 and 4-2001-435 to O.S.); Instrumentarium Research Foundation; Diabetes Research Foundation, Finland; Research Foundation of Orion Corp.; Sigrid Juselius Foundation; Foundation for Pediatric Research, Finland; and Special Federal Research Fund for University Hospitals in Finland. Disclosure Summary: T.K., P.N., P.I., M.B., E.S., A.R., T.V., H.M., T.R., and O.S. have nothing to declare. K.N. has received consulting fees from IAEA of less than $10,000. K.A.V. and J.K. have received lecture fees of less than $10,000.

P 2005 An autoradiographic study of [18F]FDG uptake to islets of Langerhans in NOD mouse. Diabetes Res Clin Pract 70:217–224 Syrota A, Dop-Ngassa M, Cerf M, Paraf A 1981 11C-L-Methionine for evaluation of pancreatic exocrine function. Gut 22:907–915 Kubota K, Yamada K, Fukada H, Endo S, Ito M, Abe Y, Yamaguchi T, Fujiwara T, Sato T, Ito K 1984 Tumor detection with carbon-11-labelled amino acids. Eur J Nucl Med 9:136 –140 Teras M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J 2007 Performance of the new generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT. Eur J Nucl Med Mol Imaging 34:1683–1692 DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214 –E223 Sokoloff L, Reivich M, Kennedy C, Des R, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M 1977 The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916 Patlak CS, Blasberg RG 1985 Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 5:584 –590 Leskinen K, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M, Joensuu H 1992 Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 33:691– 695 Peltoniemi P, Lo¨nnroth P, Laine H, Oikonen V, Tolvanen T, Gro¨nroos T, Strindberg L, Knuuti J, Nuutila P 2000 Lumped constant for [18F]fluorodeoxyglucose in skeletal muscles of obese and nonobese humans. Am J Physiol Endocrinol Metab 279:E1122–E1130 Långstro¨m B, Antoni G, Gullberg P, Halldin C, Malmborg P, Någren K, Rimland A, Sva¨rd H 1987 Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med 28:1037–1040 Någren K 1993 Quality control aspects in the preparation of [11C]-methionine. PET studies on amino acid metabolism and protein synthesis. In: Mazoyer BM, Heiss WD, Comar D, eds. Dordrecht, The Netherlands: Kluwer Academic; 81– 87 Hamacher K, Coenen HH, Stocklin G 1986 Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235–238 Bottazzo GF, Florin-Christensen A, Doniach D 1974 Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2:1279 –1283 Karjalainen JK 1990 Islet cell antibodies as predictive markers for IDDM in children with high background incidence of disease. Diabetes 39:1144 –1150 Lernmark A, Molenaar JL, van Beers WA, Yamaguchi Y, Nagataki S, Ludvigsson J, Maclaren NK 1991 The Fourth International Serum Exchange Workshop to standardize cytoplasmic islet cell antibodies. The Immunology and Diabetes Workshops and Participating Laboratories. Diabetologia 34: 534 –535 Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Ha¨ma¨la¨inen AM, Korhonen S, Kimpima¨ki T, Sjo¨roos M, Ilonen J, Knip M, Simell O 2001 Feasibility of genetic and immunological prediction of type 1 diabetes in a population-based birth cohort. Diabetologia 44:290 –297 Arnqvist H, Olsson PO, Von Schenck H 1987 Free and total insulin as determined after precipitation with polyethylene glycol: analytical characteristics and effects of sample handling and storage. Clin Chem 33:93–96 Kubatko R, Kubatko K, Yamada S, Tada M, Takahashi T, Iweta R, Tamahashi N 1994 Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 36:484 – 492 Shreve D Paul 1998 Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 25:259 –264 Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, Hosokawa M, Kohanawa M, Tamaki N 2001 Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 28:730 –735

17. 18.

19.

20. 21.

References 1. Signore A, Pozzilli P, Gale EA, Andreani D, Beverley PC 1989 The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia 32:282–289 2. Ha¨nninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O 1992 Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin dependent diabetes mellitus. J Clin Invest 90:1901–1910 3. Corstens FH, van der Meer JW 1999 Nuclear medicine’s role in infection and inflammation. Lancet 354:765–770 4. Chianelli M, Mather SJ, Martin C, Signore A 1997 Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun 18:437– 455 5. Procaccini E, Chianelli M, Pantano P, Signore A 1999 Imaging of autoimmune diseases. Q J Nucl Med 43:100 –112 6. Signore A, Chianelli M, Toscano A, Monetini L, Ronga G, Nimmon CC, Britton KE, Pozzilli P, Negri M 1992 A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies. Nucl Med Commun 13:713–722 7. Signore A, Chianelli M, Ferretti E, Toscano A, Britton KE, Andreani D, Gale EA, Pozzilli P 1994 New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2. Eur J Endocrinol 131:431– 437 8. Simpson N, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, Kilbourn M, Jurewicz A, Herold K, Liu E, Hardy M, Heertum R, Harris P 2006 Visualizing pancreatic ␤-cell mass with [11C]DTBZ. Nucl Med Biol 33:855– 864 9. Virostko J, Jansen E, Powers A 2006 Current status of imaging pancreatic islets. Curr Diab Rep 6:328 –332 10. Sweet I, Cook D, Lernmark Å, Greenbaum C, Wallen A, Marcum E, Stekhova S, Krohn K 2004 Systematic screening of potential ␤-cell imaging agents. Biochem Biophys Res Commun 314:976 –983 11. Syrota A, Duquesnoy N, Paraf A, Kellershohn C 1982 The role of positron emission tomography in the detection of pancreatic disease. Radiology 143: 249 –253 12. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T 1992 Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972–1980 13. Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, Sato N, Konishi J 2002 Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med 43:658 – 663 14. Brand K 1985 Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. Biochem J 228: 353–361 15. Brand K, Leibold W, Luppa P, Schoerner C, Schulz A 1986 Metabolic alterations associated with proliferation of mitogen-activated lymphocytes and of lymphoblastoid cell lines: evaluation of glucose and glutamine metabolism. Immunobiology 173:23–34 16. Kalliokoski T, Simell O, Haaparanta M, Viljanen T, Solin O, Knuuti J, Nuutila

22.

23.

24.

25.

26.

27.

28.

29. 30.

31.

32.

33.

34. 35.
